

HLA-DR and DQ antigen frequencies observed in SLE patients and controls from Singapore

Antigen	SLE (n = 26)		Controls (n = 77)	
	n	%	n	%
DR1	0		0	
DR2	7	26.9	21	27.3
DR3	7	26.9*	12	15.6
DR4	7	26.9	17	22.1
DR7	0		7	9.1
DR8	7	26.9	13	16.9
DR9	9	34.6	19	24.7
DR10	1	3.8	4	5.2
DR11	2	7.7	12	15.6
DR12	5	19.2	20	26.0
DR13	1	3.8	3	3.9
DR14	1	3.8	9	11.7
DQ2	6	23.6	13	16.9
DQ4	4	15.3	9	11.7
DQ5	7	26.9	18	23.4
DQ6	15	57.7	33	42.8
DQ*0601	10	38.4	23	29.9
DQ*0602	3	10.7	7	9.1
DQ*0603-8	2	7.6	3	3.9
DQ7	7	26.9	31	40.3
DQ8	5	19.2	8	10.4
DQ9	8	30.7	25	32.5

* $\chi^2 = 0.99$; odds ratio 2.0; 95% confidence interval 0.51 to 7.83; $p = 0.09$.

also a non-significant increase in DR8.⁴ However, our most striking finding was the absence of a DR2 association with SLE, as this had been found in the studies from Hong Kong and Korea^{4,5} and in a further study from Kuala Lumpur, Malaysia.⁶

One possible explanation for these differences could be genetic admixture in the Singapore Chinese population, as there has been some intermarriage with Malays, Indians, and Europeans since the seventeenth century. In contrast, Hong Kong Chinese rarely marry non-Chinese. This could explain the presence in the Singapore SLE patients of the typical white population SLE susceptibility haplotype carrying DR3 and DQ2. Another explanation could be ethnic heterogeneity among the southern Chinese. In Singapore, for example, approximately 75% of the Chinese migrated from Fujian Province, whereas 90% or more of the Hong Kong Chinese came from Guangdong Province. Unfortunately, the HLA distributions in these populations are not well characterised, but there may be significant differences which could have implications for the relative frequencies of MHC haplotypes (particularly DR2) predisposing to SLE in these populations.

MARTIN RUDWALEIT
KATHRYN GIBSON
PAUL WORDSWORTH

Nuffield Department of Clinical Medicine,
John Radcliffe Hospital, Oxford, United Kingdom

KEVIN PILE
Queen Elizabeth Hospital, Woodville, Adelaide 5011,
Australia

VERNON OH
National University Hospital, Singapore 0511

Correspondence to: Dr P Wordsworth, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom.

M Rudwaleit is supported by the Deutschen Akademischen Austauschdienst (DAAD). The authors are grateful for the financial support of the Arthritis and Rheumatism Council.

1 Deapen D, Escalante A, Weirib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. *Arthritis Rheum* 1992; 35: 311-7.

2 Hartung K, Baur M P, Coldeway R, et al. Major histocompatibility complex haplotypes and complement C4 alleles in systemic lupus

erythematosus. *J Clin Invest* 1992; 90: 1346-51.

3 Davies E J, Hillerby M C, Cooper R G, et al. HLA-DQ, DR and complement C4 variants in systemic lupus erythematosus. *Br J Rheumatol* 1993; 32: 870-5.

4 Hong G H, Kim H Y, Takeuchi F, et al. Association of complement C4 and HLA-DR alleles with systemic lupus erythematosus in Koreans. *J Rheumatol* 1994; 21: 442-7.

5 Hawkins B R, Lam Wong K, Wong R W S, Ho Chan K, Dunckley H, Serjeantson S W. Strong association between the major histocompatibility complex and systemic lupus erythematosus in southern Chinese. *J Rheumatol* 1987; 14: 1128-31.

6 Doherty D G, Ireland R, Demaine A G, et al. Major histocompatibility complex genes and susceptibility to systemic lupus erythematosus in southern Chinese. *Arthritis Rheum* 1992; 35: 641-6.

7 Wordsworth B W, Allsopp C E M, Young R P, Bell J I. HLA-DR typing using DNA amplification by the polymerase chain reaction and sequential hybridization to sequence-specific oligonucleotide probes. *Immunogenetics* 1990; 32: 413-8.

8 Bunce M, Taylor C J, Welsh K I. Rapid HLA-DQB typing by eight PCR amplifications with sequence-specific primers (PCR-SSO). *Hum Immunol* 1993; 37: 201-6.

Treatment of refractory reflex sympathetic dystrophy with pamidronate

Reflex sympathetic dystrophy (RSD) is a condition affecting part or the whole of a limb, and is characterised by pain, vasomotor disturbance and trophic changes. RSD can persist for months or years and be severely disabling.¹ On radiographs, it is characterised by local osteoporosis, which corresponds to osteoclast hyperactivity. Calcitonin, an anti-osteoclastic drug, has been shown to help some patients.² Pamidronate, a second generation bisphosphonate, is a potent anti-osteoclastic agent,³ which is the rationale for using it in the treatment of RSD.

In an open prospective study, we evaluated the efficacy of pamidronate in the treatment of refractory RSD. Eleven patients (three men and eight women; mean age 51.3 (SD 12.8) years) suffering from RSD of at least six months duration (mean of 14.6 (10.3) months), refractory to calcitonin and physical therapy, were included. All patients fulfilled Doury's criteria for the diagnosis of RSD.⁴ The involved sites were the foot (n=5), the hand (n=2), the upper limb (n=2), the knee (n=1), the lower limb (n=1). In eight cases, the RSD was related to local injury. Six patients had had to stop work because of RSD.

Radiographs of the affected sites showed osteopenia in all cases. The patients were given 30 mg of intravenous pamidronate in 500 ml of saline over four hours, daily, for three consecutive days. The patients received no standard treatment for their RSD from one month before the administration of pamidronate until three months after it. Patients were assessed by the same observer at baseline and after one and three months. Evaluation consisted of a visual analogue scale for pain (VAS), and a physician global assessment (no improvement, moderate, significant or excellent improvement) based on objective signs on clinical evaluation (hyperhidrosis, vasomotor changes, joint stiffness). Blood cell count and serum calcaemia (corrected with serum albuminaemia) were measured before, during, and one and

three days after the administration of pamidronate.

The mean VAS decreased from 58.8/100 (20.2) before therapy, to 41.1/100 (26.8) at one month ($p < 0.05$; Wilcoxon paired test) and 33.8/100 (29) at three months ($p < 0.01$). In the physician global assessment, the results were: no improvement (n=4), moderate improvement (n=1), significant improvement (n=3), and excellent improvement (n=3) at one and three months. Three of the six patients who had had to stop work had returned to work after three months. We were unable to find predictive factors for efficacy (age, gender, affected site, degree of osteopenia). Pamidronate was well tolerated, apart from classical minor adverse effects: two patients had a transient fever, two patients had brief, asymptomatic hypocalcaemia (2.05 mmol/l) and one patient had hypocalcaemia (2 mmol/l) associated with perioral paraesthesia which resolved rapidly with oral calcium treatment (1 g/day).

It is not possible to say whether the observed improvements were attributable to the treatment, the natural history of the disease, or psychological factors, as pamidronate was not compared with placebo in a double blind trial. However, more than 50% of the patients suffering from chronic disease, previously refractory to treatment, showed significant or excellent improvement while taking pamidronate, suggesting that it was effective.

In conclusion, this study suggests that pamidronate is a safe and effective drug for the treatment of some refractory cases of RSD. Further double blind trials are required to confirm these results.

JEAN FRANCIS MAILLEFERT
CHRISTINE CHATARD
SUSANNAH OWEN
THIERRY PEERE
CHRISTIAN TAVERNIER
Department of Rheumatology,
Hôpital Général, Dijon, France

JACQUES TEBIB
Department of Rheumatology,
Centre Hospitalier Lyon-Sud,
Pierre Benite, France

Correspondence to: Dr J F Maillfert, Service de Rhumatologie, Hôpital Général, 3 rue du Fb Raines, 21000 Dijon, France.

1 Chard M D. Diagnosis and management of algodystrophy. *Ann Rheum Dis* 1991; 50: 727-30.

2 Gobelet C, Meier J L, Schaffner W, Bischoff-Deloye A, Gerster J C, Burckhardt P. Calcitonin and reflex sympathetic dystrophy syndrome. *Clin Rheumatol* 1986; 5: 382-8.

3 Fitton A, McTavish D. Pamidronate. *Drugs* 1991; 41: 289-318.

4 Doury P, Dirheimer Y, Pattin S. *Algodymphy*. Berlin, Heidelberg, New York: Springer, 1981.

Pericardial tamponade preceding cutaneous involvement in systemic sclerosis

Cardiac involvement in systemic sclerosis may be primary, or secondary to involvement of other organ systems. Primary cardiac involvement in systemic sclerosis may be manifested as pericardial disease, myocardial disease, conduction system abnormalities, or cardiac arrhythmias.¹ Cardiac symptoms do not usually appear until late in the disease, but exceptionally may precede the recog-